Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA Vaccine in Lung and Renal Transplant Recipients
NCT05921903Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of GSK3003899A in respiratory syncytial virus infection (RSV) (3 arms), sponsored by GSK. Primary endpoints: RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 Over Post-Dose 1 and RSV-B Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 Over Post-Dose 1. Started Jul 2023; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05921903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921903.